Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Molecules ; 23(7)2018 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-29996473

RESUMO

In this study, 2,3-dihydro-1H-indolizinium alkaloid-prosopilosidine (PPD), that was isolated from Prosopis glandulosa, was evaluated against C. neoformans in a murine model of cryptococcosis. In vitro and in vivo toxicity of indolizidines were also evaluated. Mice were infected via the tail vein with live C. neoformans. Twenty-four hours post-infection, the mice were treated with PPD once a day (i.p.) or twice a day (bid) orally, or with amphotericin B (Amp B) intraperitoneally (IP), or with fluconazole (Flu) orally for 5 days. The brains of all of the animals were aseptically removed and the numbers of live C. neoformans were recovered. In vitro toxicity of indolizidine alkaloids was determined in HepG2 cells. PPD showed to be potent in vivo activity against C. neoformans at a dose of 0.0625 mg/kg by eliminating ~76% of the organisms compared to ~83% with Amp B (1.5 mg/kg). In addition, PPD was found to be equally efficacious, but less toxic, at either 0.125 or 0.0625 mg/kg compared to Amp B (1.5 mg/kg) when it was administered bid (twice a day) by an i.p. route. When tested by an oral route, PPD (10 mg/kg) showed potent activity in this murine model of cryptococcosis with ~82% of organisms eliminated from the brain tissue, whereas Flu (15 mg/kg) reduced ~90% of the infection. In vitro results suggest that quaternary indolizidines were less toxic as compared to those of tertiary bases. PPD (20 mg/kg) did not cause any alteration in the plasma chemistry profiles. These results indicated that PPD was active in eliminating cryptococcal infection by oral and i.p. routes at lower doses compared to Amp B. or Flu.


Assuntos
Criptococose/tratamento farmacológico , Criptococose/microbiologia , Cryptococcus neoformans/fisiologia , Indolizidinas/uso terapêutico , Prosopis/química , Administração Oral , Alcaloides/administração & dosagem , Alcaloides/química , Alcaloides/farmacologia , Alcaloides/uso terapêutico , Animais , Proteína Agonista de Morte Celular de Domínio Interatuante com BH3/metabolismo , Peso Corporal/efeitos dos fármacos , Criptococose/sangue , Cryptococcus neoformans/efeitos dos fármacos , Modelos Animais de Doenças , Feminino , Células Hep G2 , Humanos , Indolizidinas/administração & dosagem , Indolizidinas/sangue , Indolizidinas/química , Camundongos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA